BC
MDGL icon

Bayforest Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bayforest Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Buy
+44
New +$22.5K 0.02% 762
2025
Q4 		– Sell
-1,360
Closed -$624K – 888
2025
Q3 		$624K Sell
1,360
-747
-35% -$279K 0.3% 81
2025
Q2 		$638K Buy
+2,107
New +$628K 0.28% 109
2025
Q1 		– Sell
-46
Closed -$14.2K – 832
2024
Q4 		$14.2K Buy
+46
New +$12.9K 0.02% 604

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayforest Capital's MDGL Position: Q2 2026 in Review

Bayforest Capital opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 44 shares worth $23.6K. The stake represents 0.02% of the portfolio and ranks #762 among its holdings. This is a return to the name: Bayforest Capital previously reported a position in MDGL as recently as Q3 2025.

Bayforest Capital first reported a position in MDGL in Q4 2024 and has held it in 4 quarters since. The position peaked at $638K in Q2 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Bayforest Capital held 44 shares of Madrigal Pharmaceuticals worth $23.6K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Bayforest Capital position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.02% of Bayforest Capital's portfolio in Q2 2026, its #762 holding.
  • Bayforest Capital first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Bayforest Capital's Madrigal Pharmaceuticals position peaked at $638K in Q2 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.